NASDAQ:GMDA - Nasdaq - IL0011552663 - Common Stock - Currency: USD
0.0327
-0.01 (-18.25%)
The current stock price of GMDA is 0.0327 USD. In the past month the price decreased by -90.3%. In the past year, price decreased by -95.57%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The firm is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.
GAMIDA CELL LTD
PO Box 34670
JERUSALEM 95484 IL
CEO: Julian Adams
Employees: 143
Company Website: https://www.gamida-cell.com/
Phone: 97226595666
The current stock price of GMDA is 0.0327 USD. The price decreased by -18.25% in the last trading session.
The exchange symbol of GAMIDA CELL LTD is GMDA and it is listed on the Nasdaq exchange.
GMDA stock is listed on the Nasdaq exchange.
10 analysts have analysed GMDA and the average price target is 4.42 USD. This implies a price increase of 13416.73% is expected in the next year compared to the current price of 0.0327. Check the GAMIDA CELL LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GAMIDA CELL LTD (GMDA) has a market capitalization of 4.34M USD. This makes GMDA a Nano Cap stock.
GAMIDA CELL LTD (GMDA) currently has 143 employees.
The Revenue of GAMIDA CELL LTD (GMDA) is expected to grow by 808.75% in the next year. Check the estimates tab for more information on the GMDA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GMDA does not pay a dividend.
GAMIDA CELL LTD (GMDA) will report earnings on 2024-05-07, after the market close.
GAMIDA CELL LTD (GMDA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.63).
ChartMill assigns a fundamental rating of 2 / 10 to GMDA. GMDA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months GMDA reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 49.19% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -61.65% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to GMDA. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 9.37% and a revenue growth 808.75% for GMDA